Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.44 |
| ▸ | ITGA2 | P17301 | 6/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21358736 | 1.00 | L3MBTL1 (0.48) | L3MBTL1ITGB1ITGA2ITGA4NPC1 | |
| SCHEMBL21376641 | 0.92 | ITGB1 (0.42) | L3MBTL1ITGB1ITGA2ITGA4NPC1 | |
| SCHEMBL21376372 | 0.91 | NAMPT (0.50) | L3MBTL1ITGB1ITGA4SMN1; SMN2 | |
| SCHEMBL21376638 | 0.91 | ALDH1A1 (0.46) | L3MBTL1ITGB1ITGA4NPC1RAB9A | |
| SCHEMBL21376637 | 0.91 | PPID (0.45) | L3MBTL1ITGB1ITGA2ITGA4NPC1 | |
| SCHEMBL21376639 | 0.90 | OPRM1 (0.43) | L3MBTL1ITGB1ITGA4MAPT | |
| SCHEMBL21376375 | 0.89 | POLB (0.54) | SMN1; SMN2 | |
| SCHEMBL21358730 | 0.89 | PTPN1 (0.54) | L3MBTL1ITGB1ITGA2ITGA4NPC1 | |
| SCHEMBL21358729 | 0.89 | PTPN1 (0.54) | L3MBTL1ITGB1ITGA2ITGA4NPC1 | |
| SCHEMBL21358870 | 0.87 | L3MBTL1 (0.54) | L3MBTL1ITGB1ITGA2ITGA4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| EP-3765005-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | The Regents of the University of California (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019178248-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | L3MBTL1 1683/4885ITGB1 1/4885ITGA2 3/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | L3MBTL1 1683/4885ITGB1 1/4885ITGA2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.